豚鼠动物模型评价牛口蹄疫Asia-1型灭活疫苗效力的研究

以豚鼠为试验动物模型,探索一种应用豚鼠替代牛进行牛口蹄疫Asia-1型灭活疫苗效力检验的方法.豚鼠和牛同步对6批牛口蹄疫Asia-1型灭活疫苗进行PD50效力检验,其中2批进行重复性试验.豚鼠分别在免疫后7、14、21和28天采血检测Asia-1型的中和抗体水平.统计学分析显示,测定的豚鼠PD50和牛PD50之间具有极...     

Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs

Foot-and-mouth disease (FMD) is a highly contagious and economically devastating vesicular disease of cloven-hoofed animals. In this study, we constructed and characterized the immune responses and vaccine efficacy conferred by the recombinant adenovirus co-expressing VP1 of FMDV and porcine interferon alpha as fusion protein (rAd-pIFNalpha-VP1). Six groups of female BALB/c mice each with 18 were inoculated subcutaneously twice 2-week intervals with the recombinant adenoviruses. The results showed that the levels of humoral and cell-mediated immune responses in the group inoculated with rAd-pIFNalpha-VP1 were significantly higher than those in the group inoculated with rAd-VP1+rAd-pIFNalpha (P<0.05). Then four groups of guinea pigs each with six were inoculated two times at 2-week intervals intramuscularly with rAd-pIFNalpha-VP1, commercial inactivated FMD vaccine, wild-type adenovirus (wtAd) or PBS, and the protective efficacy of rAd-pIFNalpha-VP1 was determined. The results indicated that all the guinea pigs vaccinated with rAd-pIFNalpha-VP1 as well as inactivated FMD vaccine were protected from FMDV challenge, even though the levels of neutralizing antibodies (1:32-1:40) of the animals vaccinated with rAd-pIFNalpha-VP1 was lower than that in the group inoculated with inactivated FMD vaccine (1:64-1:128). It demonstrated that the newly recombinant adenovirus rAd-pIFNalpha-VP1 might further be an attractive candidate vaccine for preventing FMDV infection in swine.     

口蹄疫病毒多基因及猪α干扰素共表达载体的构建及其免疫豚鼠效果研究

为探讨口蹄疫病毒多基因及猪α干扰素（IFN-α）基因共表达真核质粒进入临床试验的可行性,本试验用PCR方法扩增了口蹄疫病毒P12A3C及部分2B基因（P12X3C）和猪IFN-α基因,克隆到真核表达载体pBudCE4.1中,经双酶切鉴定后,将重组质粒pBudCE4.1-P12X3C-IFN-α转染BHK-21细胞中,观察目的基因的表达,并将重组质粒免疫豚鼠,检测豚鼠的血清抗体水平、中和抗体滴度及T淋巴细胞增殖情况。结果显示,经酶切鉴定及DNA序列分析成功构建了重组质粒pBudCE4.1-P12X3C-IFN-α,转染BHK-21细胞后,通过Western blotting、间接免疫荧光试验鉴定证实重组质粒能有效表达。ELISA结果显示,重组质粒pBudCE4.1-P12X3C-IFN-α比重组质粒pBudCE4.1-P12X3C能诱导机体产生更高水平的抗口蹄疫病毒的血清抗体,且中和抗体滴度也高于重组质粒pBudCE4.1-P12X3C组。MTT法检测结果表明,重组质粒pBudCE4.1-P12X3C-IFN-α组淋巴细胞增殖可达15%,而重组质粒pBudCE4.1-P12X3C组则为11%。攻毒后重组质粒pBudCE4.1-P12X3C-IFN-α组和灭活疫苗组保护率达100%,高于重组质粒pBudCE4.1-P12X3C组的80%。本试验成功构建了重组质粒pBudCE4.1-P12X3C-IFN-α,猪IFN-α作为佐剂可有效辅助口蹄疫DNA疫苗提高动物体内的免疫反应。     

Maturation of functional antibody affinity in animals immunised with synthetic foot-and-mouth disease virus.

A good correlation exists between specific neutralising antibody titre and protection against challenge with foot-and-mouth disease virus (FMDV) in infected or virus-vaccinated cattle, but not in the case of animals immunised with synthetic FMDV peptides. Therefore, mechanisms other than simple neutralisation are likely to be important in vivo. Antibody affinity may influence the protective capacity of sera from immunised animals and experiments were carried out to measure the functional affinity for synthetic FMDV peptide of sera from guinea pigs and cattle given various synthetic vaccines. In guinea pigs given a single dose of synthetic vaccine, antibody affinity increased with time after immunisation. In cattle, however, administration of a second dose of peptide 21 days after the first markedly retarded the process of affinity maturation. For guinea pig sera of equivalent neutralising activity, those of higher functional affinity had higher protective indices than those of lower functional affinity. Knowledge of the importance of antibody affinity in protection against FMD is important for an improved understanding of the mechanisms of protection and for the design of novel vaccines.     

Induction of protective immune response against both PPRV and FMDV by a novel recombinant PPRV expressing FMDV VP1

Peste des petits ruminants (PPR) and foot-and-mouth disease (FMD) are both highly contagious diseases of small domestic and wild ruminants caused by the PPR virus (PPRV) and the FMD virus (FMDV). In this study, a recombinant PPRV expressing the FMDV VP1 gene (rPPRV/VP1) was generated and FMDV VP1 expression did not impair replication of the recombinant virus in vitro and immunogenicity in inducing neutralizing antibody against PPR in goats. Vaccination with one dose of rPPRV/VP1 induced FMDV neutralizing antibody in goats and protected them from challenge with virulent FMDV. Our results suggest that the recombinant PPRV expressing the FMDV VP1 protein is a potential dual live vectored vaccine against PPRV and FMDV.     

共表达Asia1口蹄疫病毒P1-2A-3C基因和猪IL-18基因重组鸡痘病毒构建及表达

为构建Asia1型口蹄疫重组鸡痘病毒疫苗,采集口蹄疫发病牛的水泡液及水泡皮,用RT-PCR法扩增出Asia 1型口蹄疫病毒的前体蛋白基因P1-2A片段和蛋白酶基因3C片段,分别克隆至pMD18-T载体上,通过酶切连接获得质粒pMD18-T-P1-2A-3C。再将P1-2A-3C片段与pUTAL-IL18片段连接起来,构建鸡痘病毒中间转移质粒pUTAL-P1-2A-3C-IL18。通过脂质体转染法,将pUTAL-P1-2A-3C-IL18与鸡痘病毒282E4株共感染染鸡胚成纤维细胞（chicken embryo fibroblasts,CEF）,通过BrdU三次加压筛选,筛选出重组鸡病毒株vUTAL-P1-2A-3C-IL18。经RT-PCR和间接免疫荧光法鉴定,证明所筛选的1株重组鸡痘病毒在CEF中能正确表达P1-2A-3C基因。本研究为研制安全、高效的亚洲Ⅰ型FMD重组鸡痘病毒疫苗奠定了基础。     

Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs,swine and cattle

Foot-and-mouth disease virus (FMDV) causes a highly contagious infection in cloven-hoofed animals. The format of FMD virus-like particles (VLP) as a non-replicating particulate vaccine candidate is a promising alternative to conventional inactivated FMDV vaccines. In this study, we explored a prokaryotic system to express and assemble the FMD VLP and validated the potential of VLP as an FMDV vaccine candidate. VLP composed entirely of FMDV (Asia1/Jiangsu/China/2005) capsid proteins (VP0, VP1 and VP3) were simultaneously produced as SUMO fusion proteins by an improved SUMO fusion protein system in E. coli. Proteolytic removal of the SUMO moiety from the fusion proteins resulted in the assembly of VLP with size and shape resembling the authentic FMDV. Immunization of guinea pigs, swine and cattle with FMD VLP by intramuscular inoculation stimulated the FMDV-specific antibody response, neutralizing antibody response, T-cell proliferation response and secretion of cytokine IFN-γ. In addition, immunization with one dose of the VLP resulted in complete protection of these animals from homologous FMDV challenge. The 50% protection dose (PD₅₀) of FMD VLP in cattle is up to 6.34. These results suggest that FMD VLP expressed in E. coli are an effective vaccine in guinea pigs, swine and cattle and support further development of these VLP as a vaccine candidate for protection against FMDV.     

O型口蹄疫病毒P1-2A3C基因在家蚕杆状病毒表达系统中的表达

口蹄疫是一种严重危害畜牧业生产的烈性传染病。为了促进O型口蹄疫病毒(FMDV)基因工程活载体疫苗的研制,选取O型FMDV编码序列中的衣壳蛋白前体P1-2A基因和蛋白酶3C基因,插入家蚕杆状病毒转移载体pVL1393中,构建重组载体pVL-P1-2A3C,并与线性化病毒Bm-BacPAK6 DNA共转染家蚕BmN细胞,获得重组病毒Bm-P1-2A3C。将重组病毒感染家蚕5龄幼虫,以双抗体夹心ELISA法和间接血凝方法检测血淋巴中的表达产物:目的蛋白在感染病毒后120 h的蚕血淋巴中表达量最高,抗原表达呈阳性的最大稀释倍数为1∶128。结果显示O型FMDV的P1-2A3C基因已在家蚕体内获得表达。     

The efficacy of FMD vaccine reduced non-structural proteins with a mAb against 3B protein

A monoclonal antibody, 3BIgG, against the prokaryotically expressed foot-and-mouth disease virus (FMDV) non-structural protein (NSP) 3B was obtained. The 3BIgG-sepharose conjugant (3BmAb-6BFF) was prepared by adding the purified 3BIgG into epoxy-activated sepharose 6BFF, incubating with the inactivated FMDV, and then removing the sepharose by centrifugation. The vaccine was made from the supernatant emulsified with oil-adjuvant ISA206. Ten guinea pigs, 26 pigs and six cattle were vaccinated, and a vaccination control group was included without treatment with 3BmAb-6BFF. After 28 days, 9/10 pigs challenged with FMDV were protected, this result was the same as the control group, indicating that the vaccine potency was not reduced after treatment with 3BmAb-6BFF. The other animals were vaccinated weekly for nine weeks, and serum samples were collected to detect 3ABC-antibody titers. The results showed that 3ABC-antibody production was delayed and the positive antibody rates were lower when vaccination was carried out using vaccines treated with 3BmAb-6BFF compared with untreated vaccines. The findings of this study suggest that it is possible to reduce NSPs using a mAb-sepharose conjugant in FMD vaccines without reducing their efficacy.     

Difference in protective immunity of the tongue and feet of guinea pigs vaccinated with foot-and-mouth disease virus type A12 following intradermolingual and footpad challenge

Immunity to Foot-and-Mouth Disease Virus (FMDV) type A12 was developed in guinea pigs by vaccinating them with varying doses of inactivated FMDV inoculated by different routes. Vaccinated animals and FMDV convalescent animals were then tested for differences in protective immunity by challenging each animal with 10³ median guinea pigs infectious doses of FMDV intradermally into the tongue and the heelpad of a rear foot. Protected immunity was evaluated by examining the tongue and feet for the development of vesicles. Protective immunity of the tongue was found to be different from that of the feet. This led to the finding that three levels of protective immunity (LPI) could be distinguished. Convalescent guinea pigs demonstrated the highest level of protective immunity (LPI-1). They did not develop vesicles after a tongue or heelpad challenge. The second level of protective immunity (LPI-2) was shown by animals vaccinated with high doses of FMDV. After a tongue and heelpad challenge, they developed vesicles on the inoculated heelpad, but not on the tongue. The lowest level of protective immunity (LPI-3) was shown by animals vaccinated with lower doses of FMDV. After a tongue and heelpad challenge, they developed vesicles on the tongue and the inoculated foot, but FMDV did not spread to the uninoculated feet. Anti-FMDV antibody titers could not predict the level of protective immunity. Other experimental results show that protective immunity in the heelpad is complex and more difficult to induce than that of the tongue. In addition, the results show the feasibility of using double site challenges of the tongue and a foot for measuring protective immunity in guinea pigs.     

Recombinant pseudorabies virus expressing P12A and 3C of FMDV can partially protect piglets against FMDV challenge

One of the crucial factors for evaluation of an effective genetically engineered vaccine is whether susceptible animals are protected from virus challenge after vaccination. In this study, a recombinant pseudorabies virus (PRV-P12A3C) that expressed capsid precursor polypeptide P12A and nonstructural protein 3C of foot-and-mouth disease virus (FMDV) was used as a vaccine. The expression of P12A3C and its immunogenicity and protective efficacy against FMDV challenge were measured. Humoral and cellular immune responses were evaluated after each immunization. Subsequently, each piglet was challenged with 1000 ID₅₀ (50% infection dose) FMDV serotype O, named OR/80, which is used to produce vaccine in China. PRV-P12A3C induced a high level of neutralizing antibody and FMDV-specific lymphocytes. Inactivated vaccine provided 100% protection, and the vector strain (TK⁻/gE⁻/gI⁻) showed no protection. PRV-P12A3C induced 60% protection, compared with piglets that were vaccinated with TK⁻/gE⁻/gI⁻. The severity of clinical signs for the remaining two piglets was lighter and the appearance of vesicles was delayed.     

FMDV免疫活性串联片段FA的表达及免疫原性测定

将口蹄疫病毒免疫串联片段FA克隆至原核表达载体pBAD/TOPO中,经鉴定后得到重组质粒pBAD-FA,将此重组质粒转化到受体菌TOP10中,用诱导剂阿拉伯醛糖分别以不同的浓度进行诱导,并在不同诱导时间进行采样,经处理后做SDS-PAGE、Westem blot分析.结果发现以终浓度为O.002%的阿拉伯醛糖进行诱导,4 h后表达可达到高峰,其大小约为23 kD,软件扫描结果显示,FB融合蛋白的表达量占细菌总蛋白的29.3%,能与抗FMDV抗体发生特异性反应,融合蛋白以包涵体和可溶形式存在.将融合蛋白的可溶性组分用50%Ni-NTA树脂过柱纯化并抽提融合蛋白的包涵体,经过洗涤后分别制成油乳剂疫苗,经皮下注射免疫豚鼠,用乳鼠中和试验测定豚鼠血清中和指数,并用口蹄疫病毒对豚鼠进行攻毒.结果表明,用此融合蛋白可溶部分的纯化产物和包涵体免疫豚鼠能诱导产生高滴度的中和抗体,对病毒的攻击分别提供100%和75%的免疫保护.     

Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18

Two recombinant fowlpox viruses (rFPV-P1 and rFPV-IL18-2AP12A) containing foot-and-mouth disease virus (FMDV) capsid polypeptide, 3C coding regions of O/NY00 were evaluated to determine their abilities to induce humoral and cellular responses in the presence or absence of swine IL-18 as genetic adjuvant. The ability to protect swine against homologous virus challenge was examined. All swine were given booster vaccinations at 21 days after the initial inoculation and were challenged 10 days after the booster vaccination. Control groups were inoculated with wild-type fowlpox virus (wtFPV). All animals vaccinated with rFPV-P12A and rFPV-IL18-P12A developed specific anti-FMDV ELISA antibody and neutralizing antibody and T-lymphocyte proliferation was observed. Cellular immune function was evaluated via examination of IFN-gamma production in swine peripheral blood serum. The results demonstrate the potential viability of a fowlpox virus-based recombinant vaccine in the control and prevention of FMDV infections.     

A peptide of foot-and-mouth disease virus serotype Asia1 generating a neutralizing antibody response, and an immunostimulatory peptide

The epitopes of the capsid of foot-and-mouth disease virus (FMDV) play important roles in the construction of highly immunogenic subunit vaccines. However few epitopes have been found for FMDV serotype Asia1. In this study we screened for epitopes of the VP1 and VP2 proteins of FMDV serotype Asia1 isolate, YNBS/58. Fragments consisting of amino acids 133-163 of VP1 and amino acids 1-33 of VP2 contained epitopes, and both induced lymphoproliferation in guinea pigs. Only the VP1 fragment induced neutralizing antibodies but the VP2 peptide dramatically increased the neutralizing antibody response induced by the VP1 peptide.     

Porcine interferon-gamma protects swine from foot-and-mouth disease virus (FMDV)

Porcine interferon-gamma (PoIFN-gamma) fused with glutathione S-transferase (GST) was expressed in Escherichia coli BL(21). Twenty 6-week-old piglets were randomly assigned to four groups. Pigs in groups 1-3 were pretreated with 30 mg, 20 mg, and 10 mg recombinant PoIFN-gamma (rPoIFN-gamma), respectively. Pigs in group 4 (control) were pretreated with GST expressed by the empty plasmid. At 48h postinoculation (hpi), all swine were challenged with FMDV (serotype O). Pigs pretreated with 30 mg rPoIFN-gamma were completely protected from virulent FMDV attack. Pigs given 20 mg rPoIFN-gamma achieved partial protection, and the unprotected piglets showed clinical signs from 68h postchallenge (hpc). Although 10 mg rPoIFN-gamma did not confer protection against FMDV, the pigs pretreated with this dose of rPoIFN-gamma presented clinical signs from 35 hpc, which was later than the control group (14 hpc). These results indicate that PoIFN-gamma can protect swine against attack from FMDV or delay the appearance of clinical signs; the effect is dose dependent.     

A complex-trapping-blocking (CTB) ELISA, using monoclonal antibodies and detecting specifically antibodies directed against foot-and-mouth disease types A, O and C. II. Application

The complex-trapping-blocking (CTB) enzyme-linked immunosorbent assay (ELISA) was evaluated to detect antibodies directed against foot-and-mouth disease virus (FMDV) strains A10 Holland, O1 BFS, and C1 Detmold. Log10 serum titres of uninfected, unvaccinated cattle (n = 100) were less than 1.80 in the CTB-ELISA. Sera from cattle vaccinated with either monovalent or trivalent vaccines were tested in both the CTB-ELISA and the serum neutralisation test (SNT); titres in both tests correlated positively (P less than 0.001). Titres of sera from cattle, sheep, and pigs vaccinated twice with FMDV A10 Holland also correlated positively in both tests. In another experiment, cattle vaccinated with FMDV strain C1 Detmold were intradermolingually challenged 3 weeks after primary vaccination; at the same time two controls were challenged. At 8 days after challenge, serum titres of the controls were distinctly higher in the CTB-ELISA than in the SNT, whereas serum titres of the vaccinated cattle were equally high in both tests. In potency tests for monovalent vaccines against FMDV strains A10 Holland, O1 BFS or C1 Detmold, serum titres correlated strongly in both tests with protection against the homologous FMDV strain. We concluded that the CTB-ELISA is not only sensitive, but easier to perform and more rapid and reproducible than the SNT. The CTB-ELISA may be useful in evaluating the immune response in cattle during FMD vaccine potency tests.     

口蹄疫病毒P1-2A和3C蛋白重组腺病毒的构建及其免疫原性研究

为研制口蹄疫病毒(FMDV)的新型重组腺病毒疫苗,本研究通过RT-PCR扩增FMDV GD株3C、P1、P1-2A、L-P1和L-2A基因,分别构建重组腺病毒穿梭质粒,并在含有腺病毒骨架质粒pAdEasy-1的BJ5183E.coli中同源重组获得腺病毒重组质粒pAd-3C、pAd-P1、pAd-P1-2A、pAd-L-P1、pAd-L-2A,经PacⅠ线性化后转染AD-293细胞,获得含有目的基因的重组腺病毒。将具有感染能力的复制缺陷型重组腺病毒rAd-3C分别与rAd-P1、rAd-P1-2A、rAd-L-P1、rAd-L-2A共感染Vero细胞,裂解细胞收集细胞上清液并进行小鼠免疫试验。经ELISA检测表明,重组腺病毒rAd-3C分别与rAd-P1-2A、rAd-L-2A共感染Vero细胞上清液能够诱导小鼠产生特异性体液免疫应答。     

Porcine B-cell activating factor promotes anti-FMDV antibodies in vitro but not in vivo after DNA vaccination of pigs

‘B-cell activating factor belonging to the TNF family’ (BAFF) represents a cytokine produced by antigen presenting cells promoting B-cell maturation, activation and immunoglobulin class switching. In the present study, we demonstrate expression of BAFF on cultured monocyte-derived dendritic cells, which is further enhanced by interferon- or interferon-γ treatment. From these cells, porcine BAFF was cloned and the recombinant protein was expressed in mammalian cells with and without a FLAG tag at the carboxyl terminus. Only the protein without the FLAG tag was bioactive in vitro, and promoted B-cell survival and the differentiation of foot-and-mouth disease virus (FMDV)-specific memory B cells into antibody producing cells. Based on this result it was tested whether BAFF can enhance FMDV antibody responses in the context of a DNA vaccination. To this end, pigs were immunised with the anti-FMDV DNA vaccine plasmid pcDNA3.1/P1-2A3C3D and a pCI plasmid expressing porcine BAFF. Using a needle-free transdermal application method, also referred to as ‘jet injection’, pigs were vaccinated three times and their humoral response quantified by ELISA and a virus neutralisation test. After the third vaccination, three out of six animals vaccinated with the pcDNA3.1/P1-2A3C3D alone but none of the animals that also received the BAFF expressing plasmid had seroconverted. These data suggest that BAFF is not appropriate as a genetic adjuvant when applied as a simple co-injection with the antigen-encoding plasmid.     

口蹄疫病毒3C蛋白酶的结构及功能研究进展

口蹄疫病毒能引起牛、羊等偶蹄动物发生高度接触性的传染病口蹄疲,该病常常影响着全球畜牧业的发展.FMDV是小RNA病毒科口蹄疫病毒属的成员,口蹄疫病毒为单股正链RNA病毒,病毒基因组全长约8.5 kb,基因组分为5'非编码区、3'非编码区和一个开放阅读框(ORF).基因组的中部是一大的开放阅读框,编码一多聚蛋白,多聚蛋白在翻译的同时,经二级裂解后,形成3种病毒结构蛋白(VP0,VP3和VP1)和8种非结构蛋白(L,2A,2B,2C,3A,3B,3C和3D).其中3C全长639 bp,编码213个氨基酸.3C蛋白酶是小RNA病毒的共同裂解酶,在多聚蛋白成熟过程中起着极为重要的作用,且在抗病毒药物打靶方面具有一定研究价值.因此,对3C蛋白酶的结构及功能研究进展进行综述很有必要.     

A recombinant 31.5 kDa keratinase and a crude exo-antigen from Microsporum canis fail to protect against a homologous experimental infection in guinea pigs

A Microsporum canis recombinant 31.5 kDa keratinase and a M. canis crude exo-antigen were tested as vaccines in an experimental infection model in guinea pigs. Animals were vaccinated subcutaneously three times at two-week intervals with either the keratinase, the exo-antigen or the adjuvant alone. Cutaneous challenge was performed blindly. Both humoral and cellular-specific immune responses to M. canis antigens were evaluated every 14 days, while a blind evaluation of clinical lesion development and fungal persistency in skin were monitored weekly. Vaccination induced very high and significant (P < 0.01) antibody responses towards both antigens. High cell-mediated immune responses to both immunogens were also induced by vaccination. After challenge, however, scores reflecting the severity of dermatophytic lesions did not differ significantly between vaccinated and control groups at any time after challenge. These results suggest that, in the guinea pig, the induction of specific immune responses against the M. canis-secreted antigens used in this study are not protective against challenge exposure.